Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Amin H Nassar,So Yeon Kim,Jacqueline V Aredo,Jamie Feng,Frances Shepherd,Chao Xu,David Kaldas,Jhanelle E Gray,Thomas J Dilling,Joel W Neal,Heather A Wakelee,Yufei Liu,Steven H Lin,Tariq Abuali,Arya Amini,Yunan Nie,Tejas Patil,Anastasiya Lobachov,Jair Bar,Bailey Fitzgerald,Yu Fujiwara,Thomas U Marron,Rohit Thummalapalli,Helena Yu,Dwight H Owen,John Sharp,Saira Farid,Pedro Rocha,Edurne Arriola,Angelica D'Aiello,Haiying Cheng,Ryan Whitaker,Kaushal Parikh,Yash Ashara,Luxi Chen,Kamya Sankar,Jeremy P Harris,Misako Nagasaka,Adanma Ayanambakkam,Ana I Velazquez,Meera Ragavan,Jessica J Lin,Zofia Piotrowska,Molly Wilgucki,Joshua Reuss,Heike Luders,Christian Grohe,Javier Baena Espinar,Ella Feiner,Salman R Punekar,Shruti Gupta,Ticiana Leal,David J Kwiatkowski,Raymond H Mak,Elio Adib,Abdul Rafeh Naqash,Sarah B Goldberg
DOI: https://doi.org/10.1016/j.jtho.2024.01.012
Abstract:Introduction: Durvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. The optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown. Methods: In this multi-institutional, international retrospective analysis across 24 institutions, we evaluated outcomes in patients with stage III EGFRmut NSCLC treated with concurrent CRT followed by consolidation therapy with osimertinib, durvalumab, or observation between 2015 and 2022. Kaplan-Meier method was used to estimate real-world progression-free survival (rwPFS, primary end point) and overall survival (secondary end point). Treatment-related adverse events (trAEs) during consolidation treatment were defined using Common Terminology Criteria for Adverse Events version 5.0. Multivariable Cox regression analysis was used. Results: Of 136 patients with stage III EGFRmut NSCLC treated with definitive concurrent CRT, 56 received consolidation durvalumab, 33 received consolidation osimertinib, and 47 was on observation alone. Baseline characteristics were similar across the three cohorts. With a median follow-up of 46 months for the entire cohort, the median duration of treatment was not reached (NR) for osimertinib (interquartile range: NR-NR) and was 5.5 (interquartile range: 2.4-10.8) months with durvalumab. After adjusting for nodal status, stage III A/B/C, and age, patients treated with consolidation osimertinib had significantly longer 24-month rwPFS compared to those treated with durvalumab or in the observation cohorts (osimertinib: 86%, durvalumab: 30%, observation: 27%, p < 0.001 for both comparisons). There was no difference in rwPFS between the durvalumab and the observation cohorts. No significant difference in overall survival across the three cohorts was detected, likely due to the limited follow-up. Any-grade trAE occurred in 52% (2 [6.1%] grade ≥3) and 48% (10 [18%] grade ≥3) of patients treated with osimertinib and durvalumab, respectively. Of 45 patients who progressed on consolidation durvalumab, 37 (82%) subsequently received EGFR tyrosine kinase inhibitors. Of these, 14 (38%) patients developed trAEs including five patients with pneumonitis (14%; 2 [5.4%] grade ≥3) and five patients with diarrhea (14%; 1 [2.7%] grade ≥3). Conclusions: This study suggests that among patients with stage III unresectable NSCLC with a sensitizing EGFR mutation, consolidation osimertinib was associated with a significantly longer rwPFS compared to durvalumab or observation. No unanticipated safety signals were observed with consolidation osimertinib.